Journal Article DZNE-2025-00618

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
SCD-plus features and AD biomarkers in cognitively unimpaired samples: A meta-analytic approach for nine cohort studies.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2025
Wiley Hoboken, NJ

Alzheimer's and dementia 21(5), e14307 () [10.1002/alz.14307]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: Specific features of subjective cognitive decline (SCD-plus) have been proposed to indicate an increased risk of preclinical Alzheimer's disease (AD). However, few studies have examined how these features relate to AD biomarkers in cognitively unimpaired (CU) older adults.Meta-analyses were performed using cross-sectional data from nine cohorts (n = 7219, mean age (SD): 71.17 (5.9), 56.5% female) to determine associations of SCD-plus features with positron emission tomography (PET)- or cerebrospinal fluid (CSF)-derived amyloid beta (Aβ) and tau biomarkers.Participants with preclinical AD (community-based only) were more likely to fulfill SCD-plus features. The presence of self-reported memory decline, associated concern/worry, and a higher number of fulfilled features were all associated with high Aβ levels. Only the latter was associated with abnormal tau.Simultaneous endorsement of multiple SCD-plus features is a robust indicator of abnormal AD biomarkers in CU older adults, whereas isolated SCD features seem only sensitive to elevated Aβ, supporting their value as early behavioral markers of preclinical AD.About two-tenths of our sample had abnormal amyloid beta (Aβ) levels with evidence of subjective cognitive decline (SCD). Preclinical AD subsamples (community-based) had a higher percentage of participants meeting SCD-plus features. Self-reported memory decline and concern/worry were the sole features associated with high Aβ, but not tau, burden. A higher number of fulfilled SCD-plus features are linked to high Aβ and tau burden. Use of multiple SCD-plus features may help identify early stages of biological AD.

Keyword(s): Humans (MeSH) ; Biomarkers: cerebrospinal fluid (MeSH) ; Alzheimer Disease: cerebrospinal fluid (MeSH) ; Alzheimer Disease: diagnosis (MeSH) ; Alzheimer Disease: diagnostic imaging (MeSH) ; Cognitive Dysfunction: cerebrospinal fluid (MeSH) ; Cognitive Dysfunction: diagnosis (MeSH) ; Amyloid beta-Peptides: cerebrospinal fluid (MeSH) ; tau Proteins: cerebrospinal fluid (MeSH) ; Positron-Emission Tomography (MeSH) ; Female (MeSH) ; Male (MeSH) ; Aged (MeSH) ; Cohort Studies (MeSH) ; Cross-Sectional Studies (MeSH) ; Alzheimer's disease ; SCD‐Initiative ; amyloid pathology ; cerebrospinal fluid ; meta‐analysis ; positron emission tomography ; subjective cognitive decline ; tau burden ; Biomarkers ; Amyloid beta-Peptides ; tau Proteins

Classification:

Contributing Institute(s):
  1. Neuropsychology (AG Wagner)
  2. Clinical Alzheimer’s Disease Research (AG Jessen)
  3. Clinical Neurophysiology and Memory (AG Düzel)
Research Program(s):
  1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
Experiment(s):
  1. Longitudinal Cognitive Impairment and Dementia Study

Appears in the scientific report 2025
Database coverage:
Medline ; Creative Commons Attribution CC BY 4.0 ; OpenAccess ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > BN DZNE > BN DZNE-AG Jessen
Institute Collections > MD DZNE > MD DZNE-AG Düzel
Institute Collections > BN DZNE > BN DZNE-AG Wagner
Full Text Collection
Public records
Publications Database

 Record created 2025-05-19, last modified 2025-06-04